Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2007 2
2008 1
2013 2
2014 4
2015 4
2016 3
2017 4
2018 6
2019 4
2020 3
2021 10
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of PARP4 as a candidate breast cancer susceptibility gene.
Prawira A, Munusamy P, Yuan J, Chan CHT, Koh GL, Shuen TWH, Hu J, Yap YS, Tan MH, Ang P, Lee ASG. Prawira A, et al. Breast Cancer Res Treat. 2019 Aug;177(1):145-153. doi: 10.1007/s10549-019-05286-w. Epub 2019 May 22. Breast Cancer Res Treat. 2019. PMID: 31119570
PURPOSE: PARP4 has been proposed as a candidate breast cancer susceptibility gene. However, its function and involvement in breast carcinogenesis is unclear. We sought to determine the variant frequency of PARP4 in BRCA-negative women referred for genetic testing fr …
PURPOSE: PARP4 has been proposed as a candidate breast cancer susceptibility gene. However, its function and involvement in breast ca …
Rational design of selective inhibitors of PARP4.
Kirby IT, Person A, Cohen M. Kirby IT, et al. RSC Med Chem. 2021 Oct 4;12(11):1950-1957. doi: 10.1039/d1md00195g. eCollection 2021 Nov 17. RSC Med Chem. 2021. PMID: 34825190 Free PMC article.
Herein we describe the rational design of selective small molecule inhibitors of PARP4 (also known as vPARP). These inhibitors are based on a quinazolin-4(3H)-one scaffold, and contain substituents at the C-8 position designed to exploit a unique threonine (Thr484, human …
Herein we describe the rational design of selective small molecule inhibitors of PARP4 (also known as vPARP). These inhibitors are ba …
Structural and biochemical analysis of the PARP1-homology region of PARP4/vault PARP.
Frigon L, Pascal JM. Frigon L, et al. Nucleic Acids Res. 2023 Dec 11;51(22):12492-12507. doi: 10.1093/nar/gkad1064. Nucleic Acids Res. 2023. PMID: 37971310 Free PMC article.
PARP4 is an ADP-ribosyltransferase that resides within the vault ribonucleoprotein organelle. Our knowledge of PARP4 structure and biochemistry is limited relative to other PARPs. ...
PARP4 is an ADP-ribosyltransferase that resides within the vault ribonucleoprotein organelle. Our knowledge of PARP4 structure …
Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with multiple primary tumors including thyroid cancer.
Cirello V, Colombo C, Pogliaghi G, Proverbio MC, Rossi S, Mussani E, Tosi D, Bulfamante G, Bonoldi E, Gherardi G, Persani L, Fugazzola L. Cirello V, et al. Mutat Res. 2019 Nov;816-818:111672. doi: 10.1016/j.mrfmmm.2019.111672. Epub 2019 Jun 1. Mutat Res. 2019. PMID: 31203137
Recently, the PARP4 gene has been identified as a possible susceptibility gene of primary thyroid and breast cancers. ...Consistently, immunostaining for PARP4 protein was negative at nuclear level in all tissues, thus suggesting that PARP4P2 pseudogene variant coul …
Recently, the PARP4 gene has been identified as a possible susceptibility gene of primary thyroid and breast cancers. ...Consistently …
Germline PARP4 mutations in patients with primary thyroid and breast cancers.
Ikeda Y, Kiyotani K, Yew PY, Kato T, Tamura K, Yap KL, Nielsen SM, Mester JL, Eng C, Nakamura Y, Grogan RH. Ikeda Y, et al. Endocr Relat Cancer. 2016 Mar;23(3):171-9. doi: 10.1530/ERC-15-0359. Epub 2015 Dec 23. Endocr Relat Cancer. 2016. PMID: 26699384 Free PMC article.

Kaplan-Meier analysis using Gene Expression Omnibus (GEO), European Genome-phenome Archive (EGA) and The Cancer Genome Atlas (TCGA) datasets showed poor relapse-free survival (P < 0.001, Hazard ratio 1.27) and overall survival (P = 0.006, Hazard ratio 1.41) in a PARP4 l

…
Kaplan-Meier analysis using Gene Expression Omnibus (GEO), European Genome-phenome Archive (EGA) and The Cancer Genome Atlas (TCGA) datasets …
Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance.
Sung HY, Han J, Chae YJ, Ju W, Lee Kang J, Park AK, Ahn JH. Sung HY, et al. BMB Rep. 2023 Jun;56(6):347-352. doi: 10.5483/BMBRep.2022-0202. BMB Rep. 2023. PMID: 37013346 Free PMC article.
Reduced PARP4 expression was restored by treating cisplatin-sensitive cell lines with a demethylation agent, implicating the epigenetic regulation of PARP4 expression by promoter methylation. ...The results showed significantly increased PARP4 mRNA expression …
Reduced PARP4 expression was restored by treating cisplatin-sensitive cell lines with a demethylation agent, implicating the epigenet …
Modification Effect of PARP4 and ERCC1 Gene Polymorphisms on the Relationship between Particulate Matter Exposure and Fasting Glucose Level.
Kim JH, Lee S, Hong YC. Kim JH, et al. Int J Environ Res Public Health. 2022 May 20;19(10):6241. doi: 10.3390/ijerph19106241. Int J Environ Res Public Health. 2022. PMID: 35627777 Free PMC article.
To evaluate the relationships between exposures to PM(10), PM(2.5-10), and PM(2.5); the serum level of fasting glucose, a key IR indicator; and effects of polymorphisms of two repair genes (PARP4 and ERCC1) on these relations, PMs exposure data and blood samples for glucos …
To evaluate the relationships between exposures to PM(10), PM(2.5-10), and PM(2.5); the serum level of fasting glucose, a key IR indicator; …
Modification of PARP4, XRCC3, and RAD51 Gene Polymorphisms on the Relation between Bisphenol A Exposure and Liver Abnormality.
Kim JH, Hong YC. Kim JH, et al. Int J Environ Res Public Health. 2020 Apr 17;17(8):2794. doi: 10.3390/ijerph17082794. Int J Environ Res Public Health. 2020. PMID: 32316696 Free PMC article.
A significant association between BPA levels and liver abnormality was found only in elders with the PARP4 G-C-G haplotype, XRCC3 G-A-G haplotype, or RAD51 T-A-A haplotype (odds ratio (OR) = 2.16 and p = 0.0014 for PARP4; OR = 1.57 and p = 0.0249 for XRCC3; OR = 1.4 …
A significant association between BPA levels and liver abnormality was found only in elders with the PARP4 G-C-G haplotype, XRCC3 G-A …
Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ, Westin SN, Coleman RL. Dal Molin GZ, et al. Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fon-2018-0215. Epub 2018 Aug 14. Future Oncol. 2018. PMID: 30105925 Free PMC article. Review.
Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as treatment in patients with recurrent high-grade ovarian ca …
Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, …
Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics.
Richard IA, Burgess JT, O'Byrne KJ, Bolderson E. Richard IA, et al. Front Cell Dev Biol. 2022 Jan 14;9:801200. doi: 10.3389/fcell.2021.801200. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35096828 Free PMC article. Review.
Many other members of the PARP protein family share catalytic domain homology with PARP1/2, however, these proteins are comparatively understudied, particularly in the context of DNA damage repair and tumourigenesis. This review explores the functions of PARP4,6-16 and dis …
Many other members of the PARP protein family share catalytic domain homology with PARP1/2, however, these proteins are comparatively unders …
49 results